Con

摘要

Antimuscarinic medications are a cornerstone of treatment for urge urinary incontinence. Clinical trials have demonstrated a clear benefit of these agents over placebo in reducing urge incontinence episodes with cure/improved rates of 50% to 60%. A contrarian may look at these results and point out that 40% to 50% of well chosen and motivated clinical trial subjects will not observe a benefit from treatment. Furthermore, multiple studies have demonstrated that patient compliance with medications over time is poor, with as many as 85% discontinuing treatment after 12 months.